Search Results
327 results
Your search is now limited to «Novartis» expert search.
FiercePharma 03/22/2019 10:26
RELATED: Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects The spinoff marks the end of almost 11 years of Novartis’ connection with Alcon.
More from FiercePharma:
ENDPOINTS 03/22/2019 09:24
Novartis’ eye care business Alcon — being spun off by the Swiss drugmaker — will start trading on the Swiss market and NYSE on April 9.
More from ENDPOINTS:
pharmaphorum 03/22/2019 08:32
Each Novartis shareholder will receive one share for every five Novartis shares or American depositary receipts that they hold at the close of business on April 8.
More from pharmaphorum:
FierceMedicalDevices 03/22/2019 06:22
Conatus and Novartis suffer another midphase NASH flop.
More from FierceMedicalDevices:
GlobeNewswire 03/22/2019 02:01
Between the ADR record date of April 1, 2019 and through April 10, 2019, Novartis ADR holders cannot convert their Novartis ADRs into Novartis ordinary shares and vice versa.
More from GlobeNewswire:
FiercePharmaManufacturing 03/21/2019 10:25
Novartis’ internal probe, expert panel find no suspicious payments to Greek officials.
More from FiercePharmaManufacturing:
Fortune 03/20/2019 14:50
Vasant Narasimhan is bringing a unique brand of leadership to his job as CEO of Novartis (NVS.
More from Fortune:
STAT 03/20/2019 09:27
Johnson & Johnson will discontinue use of a forced swim test for antidepressant research, after pressure from the People for Ethical Treatment of Animals.
More from STAT:
FeedNavigator 03/19/2019 07:57
In intervention counties, public and non-profit health facilities were allowed to purchase Novartis Access medicines from the Mission for Essential Drugs and Supplies (MEDS.
More from FeedNavigator:
Zacks.com 03/18/2019 15:53
Last month, Novartis’ shareholders approved the proposed 100% spin-off of the Alcon eye-care division.
More from Zacks.com:
WN.com 03/16/2019 13:32
EAST HANOVER, N.J., March 16, 2019 /PRNewswire/ -- Novartis announced today new results from a 4-week extension of the landmark PIONEER-HF trial, presented as a late-breaker at the American College of Cardiology's 68th Annual Scientific Session. Data from the 8-week double-blind PIONEER-HF trial, first presented in November 2018 at the American Heart Association Scientific Sessions, showed the benefits of in-hospital initiation in appropriate stabilized patients of Entresto tablets on a systolic heart failure (HF) biomarker, safety and clinical outcome.2 All patients received open-label Entresto during the 4-week extension period, and data showed reductions in both groups in the HF biomarker...
More from WN.com:
PR Newswire 03/16/2019 13:15
Novartis is committed to providing patients with affordable access and resources through Entresto Central.
More from PR Newswire:
World Pharma News 03/15/2019 05:00
The Novartis Institute for Tropical Diseases (NITD), the Genomics Institute of the Novartis Research Foundation (GNF) and collaborators have developed a promising portfolio of novel drug candidates for the treatment of kinetoplastid diseases.
More from World Pharma News:
Becker's Hospital Review 03/14/2019 18:07
The chief executive of Novartis' generic drug business Sandoz abruptly stepped down, according to Reuters.
More from Becker's Hospital Review:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications